LexDanaLexDanabeta
Inventor

Henry B. Lowman

Inventor
El Granada, CA, US

Overview

89→
Patents
1996–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 89 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
A61KPreparations for medical, dental or toiletry purposes22%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests10%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
C12NMicroorganisms or enzymes7%
C40BCombinatorial chemistry2%
C12YEnzymes1%
A01KAnimal husbandry1%
A61JContainers specially adapted for medical or pharmaceutical purposes1%
PatentTitleYear
10,894,821Activatable antibodies having non-binding steric moieties and methods of using the same202110,709,799Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof202010,533,053Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor202010,301,380Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof20199,889,211'Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof'20189,856,314'Activatable antibodies having non-binding steric moieties and methods of using the same'20189,688,748'Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof'20179,676,868'Humanized anti-factor D antibodies and uses thereof'20179,545,442'Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof'20179,540,440'Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof'20179,517,276'Compositions and methods for conjugating activatable antibodies'20169,315,583'Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis'20169,127,053'Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof'20159,120,853'Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof'20158,840,896'Anti-HER2 antibody variants'20148,753,826'Methods of detecting factor D with anti-factor D antibodies'20148,703,133'Antibody variants'20148,614,306'Polynucleotides encoding humanized anti-factor D antibodies'20138,562,992'Immunoglobulin variants and uses thereof'20138,372,403'Humanized anti-factor D antibodies and uses thereof'20138,309,300'Cysteine engineered antibodies and conjugates'20128,273,352'Humanized anti-factor D antibodies and uses thereof'20128,193,329'Nucleic acids encoding anti-factor D antibodies'20128,187,604'Methods of treating with anti-factor D antibodies'20128,110,548'Method for treating cartilage disorders'20128,097,587'IGF-I protein variants for treating IGFBP-1-related disorders'20128,067,002'Humanized anti-factor D antibodies'20117,947,650'Article of manufacture'20117,855,275'Cysteine engineered antibodies and conjugates'20107,850,966'Method of treating breast cancer using anti-HER2 antibody variants'20107,799,900'Immunoglobulin variants and uses thereof'20107,635,749'Methods and compositions for prolonging elimination half-times of bioactive compounds'20097,608,681'Methods and compositions for prolonging elimination half-times of bioactive compounds'20097,521,541'Cysteine engineered antibodies and conjugates'20097,435,797'Anti-HER2 antibody variants'20087,432,244'Method of inhibiting insulin-like growth factor-1 (IGF-1) by IGF-1-antagonist peptides'20087,423,017'Method for treating cartilage disorders'20087,375,193'Anti-VEGF antibodies'20087,365,166'Anti-VEGF antibodies'20087,351,545'IGF binding proteins'20087,348,154'IGF binding proteins'20087,297,334'Anti-vegf antibodies'20077,192,738'IGF binding proteins'20077,169,901'Anti-VEGF antibodies'20077,157,085'Method for treating IgE-mediated disorders'20077,105,167'Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant'20067,101,851'IgE receptor antagonists'20067,071,300'IGF antagonist peptides'20067,060,269'Anti-VEGF antibodies'20066,949,349'Insulin-like growth factor agonist molecules'20056,761,889'Anti-IgE antibodies'20046,750,321'Insulin-like growth factor agonist molecules'20046,743,894'Insulin-like growth factor agonist molecules'20046,723,833'Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent'20046,716,586'Insulin-like growth factor agonist molecules'20046,713,451'Insulin-like growth factor agonist molecules'20046,693,079'Insulin-like growth factor agonist molecules'20046,693,078'Insulin-like growth factor agonist molecules'20046,689,751'Insulin-like growth factor agonist molecules'20046,683,053'Insulin-like growth factor agonist molecules'20046,682,735'Anti-IgE antibodies'20046,680,298'Insulin-like growth factor agonist molecules'20046,677,305'Insulin-like growth factor agonist molecules'20046,645,775'Insulin-like growth factor agonist molecules'20036,635,619'Insulin-like growth factor agonist molecules'20036,632,794'Insulin-like growth factor agonist molecules'20036,632,926'Antibody variants'20036,620,789'Insulin-like growth factor agonist molecules'20036,608,031'Insulin-like growth factor agonist molecules'20036,608,028'Insulin-like growth factor agonist molecules'20036,509,443'IGF-I point variants'20036,506,874'IGF-I variants'20036,420,518'Insulin-like growth factor agonist molecules'20026,403,764'Insulin-like growth factor-1 protein variants'20026,290,957'Anti-IgE antibodies and method of improving polypeptides'20016,251,865'Insulin-like growth factor agonist molecules'20016,172,213'Anti-IgE antibodies and method of improving polypeptides'20016,143,523'Human growth hormone variants'20006,121,416'Insulin-like growth factor agonist molecules'20006,057,292'Method for inhibiting growth hormone action'20006,040,136'Enrichment method for variant proteins with altered binding properties'20006,022,711'Human growth hormone variants having enhanced affinity for human growth hormone receptor at site 1'20005,994,511'Anti-IgE antibodies and methods of improving polypeptides'19995,849,535'Human growth hormone variants'19985,834,598'Human growth hormone variants'19985,821,047'Monovalent phage display'19985,750,373'Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants'19985,688,666'Growth hormone variants with altered binding properties'19975,534,617'Human growth hormone variants having greater affinity for human growth hormone receptor at site 1'1996

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1996–2017Patents assigned to GENENTECH INC (77)· patent assignee history
1996–2000Based in Hercules, CA, US· patent location history
1999–2021Based in El Granada, CA, US· patent location history
2011–2016Patents assigned to LOWMAN HENRY B (10)· patent assignee history
2011–2013Patents assigned to AN LING-LING (4)· patent assignee history
2011–2013Patents assigned to FUNG SEK CHUNG (4)· patent assignee history
2011Based in El Cerrito, CA, US· patent location history
2015–2021Patents assigned to CYTOMX THERAPEUTICS INC (12)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
GENENTECH INC771996–2017
CYTOMX THERAPEUTICS INC122015–2021
LOWMAN HENRY Bself102011–2016
AN LING-LING42011–2013
FUNG SEK CHUNG42011–2013
Locations
LocationPatentsSpan
El Granada, California, US781999–2021
Hercules, California, US101996–2000
El Cerrito, California, US12011